A Mesalazine-Aloperine Co-Amorphous System for Simultaneous Dissolution Enhancement, Permeability Improvement, and Synergistic Anti-Ulcerative Colitis Activity: A Combined Pharmaceutics and Network Pharmacology Study

Background/Objectives: Mesalazine (MSZ), the first-line therapy for ulcerative colitis (UC), is a BCS Class IV drug limited by poor aqueous solubility and low intestinal permeability, which together restrict colonic drug delivery and therapeutic efficacy. This study aimed to develop a co-amorphous (CAM) system of MSZ and aloperine (ALO) to enhance MSZ dissolution and permeation while achieving anti-UC synergy.